Patent classifications
A61L2300/402
Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products
Compositions and methods for treating tissue are provided. The compositions may include tissue matrix derived from adipose tissue suitable for injection, small-volume implantation, or use as a soft-tissue regenerative material. Also provided are methods for producing such compositions.
Dura Shield
Dura shields in accordance with embodiments of the invention are disclosed. In one embodiment, a dura shield includes a shield configured to protect a patient's dura during an interbody procedure, a tether coupled to the shield and configured to position the shield, and an anchor coupled to the shield and configured to attach to a surface within the patient during the interbody procedure. A variety of sensors can be incorporated into the dura shield in order to monitor a patient during the procedure.
IMPLANTABLE SUSTAINED RELEASE DEVICE AND A METHOD OF USE THEREFOR IN THE TREATMENT OF BRAIN DISORDERS
A biocompatible and bioresorbable implantable device that is intended to be deployed in the middle meningeal artery through intra-arterial catheters and release an anesthetic agent for a prolonged period into the branches of the middle meningeal artery to treat severe headaches including migraine and trigeminal neuralgias. The implantable device may be a mesh with multiple helical loops, fenestrated collapsible hollow shell or spheroid, or folded sheath.
Controlled Release of a Hydrophilic Agent from a Coated Surface
The present invention is an implantable medical device comprising (i) a base coat layer having an inner and outer surface, the inner surface of the base coat layer contacting the implantable medical device; (ii) a top-coat layer of a hydrophilic polymer chemically crosslinked and covalently bonded to the outer surface of the base coat layer, the hydrophilic polymer comprising an anionic polyelectrolyte; and (iii) an amount of a hydrophilic cationic drug agent added to the top-coat layer sufficient to provide an effective dosage of the drug agent for delivery to a patient, whereby the hydrophilic cationic drug agent is initially adsorbed into the anionic polyelectrolyte of the top-coat layer and the hydrophilic cationic drug agent having a release rate after the medical device is implanted within a patient's body.
Adaptable Prosthetic Tissue Valves
Prosthetic valves that include conical shaped base valve members having an annular engagement end, a closed distal end region that restricts fluid flow therethrough, and a plurality of elongated ribbon members, which transition from an open fluid flow configuration to a closed fluid flow configuration in response to expansion and contraction of the base valve member, and a support structure that is configured and adapted to exert retaining forces on the annular engagement ends of the base valve members, whereby the support structure (i) conforms to the shape of the annular engagement ends of the base valve members, (ii) securely positions the annular engagement ends of the base valve members adjacent to and, thereby, in contact with a valve annulus, whereby the annular engagement ends of the base valve members conform to the shape of the valve annulus, and (iii) the annular engagement ends of the base valve members adapt to at least one fluctuation in the configuration and/or dimension of the valve annulus, whereby the annular engagement ends of the base valve members maintain contact therewith.
Reinforced Prosthetic Valves
A prosthetic valve comprising a conical shaped sheet structure and a support structure, the sheet structure having a closed distal end and a plurality of elongated ribbon members that are positioned proximate each other in a joined relationship, whereby the ribbon members form a plurality of fluid flow modulating regions that close when fluid flow through the valve exhibits a negative flow pressure and open when fluid flow through the valve exhibits a positive flow pressure, the support structure having at least one elongated cardiovascular structure engagement member that is associated with one of the ribbon members and adapted to engage a cardiovascular structure.
Hyaluronic acid-based gels including lidocaine
Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.
POLYSACCHARIDE AND PROTEIN-POLYSACCHARIDE CROSS-LINKED HYDROGELS FOR SOFT TISSUE AUGMENTATION
Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.
DRUG DELIVERY DEVICES AND METHODS
Drug delivery devices are provided in which much of a drug payload within the device remains within an area proximal to a wall of the device through which the drug must pass for release of the drug from the device into a patient. In one case, the device may include a drug reservoir portion which has a drug reservoir lumen bounded by a reservoir wall having an inner surface; a drug located in the drug reservoir lumen; and a core region which does not comprise the drug, wherein the drug is disposed between the inner surface of the reservoir wall and the core region. The device may be elastically deformable between a first shape suited for insertion through a lumen into a body cavity of the patient and a second shape suited to retain the device within the body cavity.
Dermal filler compositions including antioxidants
Provided are injectable, hyaluronic acid-based dermal filler compositions including conjugated vitamin C derivatives. The compositions provide for extended release of active vitamin C into tissue, promoting collagenesis and other benefits to skin.